Latest News and Events

May 2017

Nanomerics to Present NM147 Oral Amphotericin at Worldleish 2017

Nanomerics will be presenting data on NM147,  the MET-enabled oral form of Amphotericin B,  at the 6th World Congress on Leishmaniasis (Worldleish 2017).  The conference is organised by the WHO ColIaborating Centre for Leishmaniasis and DNDi and will be held in Toledo, Spain, from 16 to 20 May 2017. 

Nanomerics shortlisted for RSC Emerging Technologies Competition

Nanomerics today announced that its had been short listed for a Royal Society of Chemistry Emerging Technologies award. This annual award is made to companies that demonstrate the commercialisation of chemical sciences technology.  Nanomerics was short listed based on the use of its Molecular Envelope Technology, the technology underpinning Nanomerics' products, for drug delivery to the brain.
 

March 2017

Development Agreement to Tackle Glaucoma

Nanomerics has entered into a development agreement with California based NEMUS Bioscience, Inc. (OTCQB: NMUS), to develop a topical ocular formulation of tetrahydrocannabinol-valine-hemisuccinate (THCVHS), the prodrug of THC, which is the active component of Nemus drug candidate NB1111 being developed for the treatment of glaucoma. 

February 2017

Dr Sajjad Ahmad Joins Nanomerics SAB

Nanomerics' Ophthalmology SAB Strengthened

Dr Sajjad Ahmad is a consultant ophthalmologist/corneal surgeon at Moorfields Eye Hospital and honorary senior clinical lecturer at the UCL Institute of Ophthalmology. His clinical expertise is in ocular surface and corneal inflammatory disease and ocular surface/corneal/anterior segment reconstruction of the eye. He has also developed a culture system for human corneal epithelial stem cells that has been successfully used in clinical trials nationally. 
 

January 2017

September 2016

Nanomerics CSO Prof Uchegbu wins Innovative Science Award

At the recent annual International APS PharmSci conference organised by the Academy of Pharmaceutical Sciences, Professor Ijeoma Uchegbu was awarded the Innovative Science Award, sponsored by GSK for her work on translating science into practice.

March 2016

February 2016

April 2014

Prof Martin Koltzenburg Joins Nanomerics Advisory Board

Nanomerics is pleased to announce the strengthening of its Scientific Advisory Board with the appointment of Professor Martin Koltzenburg.  

Professor Koltzenburg’s appointment will  support the clinical development of Nanomerics' lead product NM0127, a novel pain therapeutic based on an endogenous peptide.